Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

sipuleucel-T

A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective antitumor immune response against tumor… Expand
  • figure 1
  • table 1
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Background Sipuleucel-T is a US Food and Drug Administration–approved immunotherapy for asymptomatic or minimally symptomatic… Expand
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PurposeSipuleucel-T, the first FDA-approved autologous cellular immunotherapy for treatment of advanced prostate cancer, is… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Sipuleucel-T was approved by the US Food and Drug Administration on April 29, 2010, as an immunotherapy for late-stage prostate… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2012
Review
2012
Cancer chemotherapy drugs have long been considered immune suppressive. However, more recent data indicate that some cytotoxic… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
New results reveal the clinical promise of antitumor immunotherapies, and highlight important considerations for the development… Expand
  • figure 1
  • table 1
  • figure 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Therapies for prostate cancer depend on age, rate of the cancer’s growth, the specific benefits and drawbacks of treatment, and… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of… Expand
  • figure 1
  • table 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Sipuleucel‐T is an investigational active cellular immunotherapy product designed to stimulate an immune response against… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?